"Seems clear that Anavex 2-73 has intellectual property protection until at least 2035."
The 2015 patent which expires in 2035 gives protection for treating cancer, but only in combinations with those 3 other compounds listed in the patent (and it's only for treating cancer, not AD). See my first post of the day.